PB2059: SENSITIVITY AND SUBGROUP ANALYSES FURTHER SUPPORT CLINICAL SIMILARITY IN EFFICACY BETWEEN ABP 959 AND ECULIZUMAB REFERENCE PRODUCT IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEM...

por Kulasekararaj, Austin, Lanza, Francesco, Arvanitakis, Alexandros, Langemeijer, Saskia, Chonat, Satheesh, Cao, Jia, Chow, Vincent, Henary, Haby
Publicado 2023

Targeting wild-type TP53 using AMG 232 in combination with MAPK inhibition in Metastatic Melanoma; a phase 1 study

por Moschos, Stergios J., Sandhu, Shahneen, Lewis, Karl D., Sullivan, Ryan J., Puzanov, Igor, Johnson, Douglas B., Henary, Haby A., Wong, Hansen, Upreti, Vijay V., Long, Georgina V., Flaherty, Keith T.
Publicado 2022

Phase 1 study of the MDM2 inhibitor AMG 232 in patients with advanced P53 wild-type solid tumors or multiple myeloma

por Gluck, W. Larry, Gounder, Mrinal M., Frank, Richard, Eskens, Ferry, Blay, Jean Yves, Cassier, Philippe A., Soria, Jean-Charles, Chawla, Sant, de Weger, Vincent, Wagner, Andrew J., Siegel, David, De Vos, Filip, Rasmussen, Erik, Henary, Haby A.
Publicado 2019